biostudies-literatureSchievink BNIA NIH HHS758-68https://www.ebi.ac.uk/biostudies/studies/S-EPMC7735387biostudies-literatureUnknown23(7)<h4>Background</h4>A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.<h4>Design</h4>We used the PRE score on data from the RADAR/JAPAN study to predict the effect of atrasentan on renal and heart failure outcomes.<h4>Methods</h4>We performed a post-hoc analysis of the RADAR/JAPAN randomized cliEuropean journal of preventive cardiologyPrediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.PMC7735387R01 AG018915R01 AG045551Toto RKitzman DWParving HHSchievink Bde Zeeuw DPerkovic VHoekman JColl BAndress DTobe SSmink PAKohan DMakino HLambers Heerspink HJBrennan JJRemuzzi GCorrea-Rotter RHou FFfalsePrediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.<h4>Background</h4>A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemoglobin, and increases body weight in patients with type 2 diabetes and nephropathy. We previously developed an algorithm, the Parameter Response Efficacy (PRE) score, which translates short-term drug effects into predictions of long-term effects on clinical outcomes.<h4>Design</h4>We used the PRE score on data from the RADAR/JAPAN study to predict the effect of atrasentan on renal and heart failure outcomes.<h4>Methods</h4>We performed a post-hoc analysis of the RADAR/JAPAN randomized cli2016-01-01T00:00:00Z2016 May2026-05-03T08:14:41.025Z2021-02-20T12:24:38ZS-EPMC77353872622908910.1177/2047487315598709